NIVOLUMAB, Bemarituzumab, OXALIPLATIN, FOLINIC ACID, Placebo for AMG 552, CAPECITABINE , FLUOROURACIL
20210098
Phase 3 small_molecule active
Quick answer
NIVOLUMAB, Bemarituzumab, OXALIPLATIN, FOLINIC ACID, Placebo for AMG 552, CAPECITABINE , FLUOROURACIL for Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression is a Phase 3 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active